



On **Thursday, 7 January**, VISION2030 will gather business-founding scientists and CEOs from the cell therapy and regenerative medicine space for in-depth interviews on a decade past and a decade ahead. Where we are now, obstacles to overcome, and what is next: for our field, businesses, careers. This gathering comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect. The program on **Friday, 8 January** will feature Industry Career talks with sponsoring companies discussing how the future of our field will shape the future of our careers – new opportunities, paths, and challenges. Attendees will hear from HR leaders and scientists, discussing the transition from academia to industry, how to make it, and what to expect. Special thanks to ISSCR VISION2030 sponsors: [STEMCELL Technologies](#), [BlueRock Therapeutics](#), [ElevateBio](#), [Agilent](#), [Catalent](#), [BioLamina](#) and [Third Rock Ventures](#).

## **Executive Interviews and Thought Leaders Panel**

**Thursday, 7 January**

**12:00-17:30 EST ([view your time zone](#))**

**12:00 EST**

### **Welcome Remarks**

**Christine L. Mummery**, *ISSCR President / Leiden University Medical Center, Netherlands*

**Deepak Srivastava**, *Gladstone Institute/UCSF, USA | ISSCR Immediate Past President*

**Leonard I. Zon**, *Boston Children's Hospital, USA | ISSCR Founder*

**12:15 EST**

### **BlueRock Therapeutics Executive Interview**

**Emile Nuwaysir**, *President and Chief Executive Officer, BlueRock Therapeutics, USA*

**Lorenz Studer**, *Founding Scientist, BlueRock Therapeutics | Sloan Kettering Institute for Cancer Research, USA*

**Viviane Tabar**, *Founding Scientist, BlueRock Therapeutics | Memorial Sloan Kettering Center, USA*

Interviewed by ISSCR Board Member **Arnold R. Kriegstein**, *University of California, San Francisco, USA*

[BlueRock Therapeutics](#) is advancing their novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

**12:45 EST**

### **Surrozen Executive Interview**

**Craig Parker**, *Chief Executive Officer, Surrozen, USA*

**Claudia Janda**, *Princes Máxima Centrum, Netherlands | Surrozen Founder*

Interviewed by ISSCR Past President **Hans C. Clevers**, *Hubrecht Institute, Netherlands | Surrozen Founder*

[Surrozen](#) is pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and restore organs damaged by serious disease.

**13:15-13:25 EST BREAK**

**13:25 EST ElevateBio Executive Interview**

**Mitchell H. Finer**, *Scientific Founder and President, ElevateBio, USA*

**Melissa K. Carpenter**, *Chief Scientific Officer, ElevateBio, USA*

Interviewed by ISSCR Board Member **Martin F. Pera**, *The Jackson Laboratories, USA* | *Stem Cell Reports* Editor-in-Chief

[ElevateBio](#) is accelerating the rate of innovation in cell and gene therapy with a disruptive capital-efficient model.

**13:55 EST STEMCELL Technologies Executive Interview**

**Allen C. Eaves**, *Scientific Founder | Chief Executive Officer, STEMCELL Technologies, Canada*

Interviewed by ISSCR Board Member **Valentina Greco**, *Yale University School of Medicine, USA*

[STEMCELL Technologies'](#) mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools and services that enable life science research.

**14:25-14:40 EST BREAK**

**14:40 EST Vertex Pharmaceuticals Executive Interview**

**Jeffrey Leiden**, *Executive Chairman, Vertex Pharmaceuticals, USA*

**Bastiano Sanna**, *Executive Vice President, Chief of Cell & Genetic Therapies & VCGT Site Head, Vertex Pharmaceuticals, USA*

Interviewed by ISSCR Past President **Douglas A. Melton**, *Scientific Founder, Semma Therapeutics, now Vertex Pharmaceuticals | Harvard University, USA*

[Vertex Pharmaceuticals](#) is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

**15:15-15:20 EST FUTURECAST--STEMCELL Technologies, Inc.**

Andrew Gaffney, Associate Director, iPSC and Differentiated Cells

**15:20 PM EST Tenaya Therapeutics Executive Interview**

**Faraz Ali**, *Chief Executive Officer, Tenaya Therapeutics, USA*

**Deepak Srivastava**, *Scientific Founder, Tenaya Therapeutics | Gladstone Institute/UCSF, USA* | ISSCR Immediate Past President

Interviewed by ISSCR Board Member **Charles E. Murry**, *Institute for Stem Cell and Regenerative Medicine, University of Washington/Sana Biotechnologies, USA*

[Tenaya Therapeutics](#) is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.

**15:50-16:00 EST BREAK**

**16:00 EST Fate Therapeutics Executive Interview**

**Scott Wolchko**, *President and Chief Executive Officer, Fate Therapeutics, USA*

**Leonard I. Zon**, *Scientific Founder, Fate Therapeutics | Boston Children's Hospital, USA* | ISSCR Founder

Interviewed by ISSCR Board Member **Takanori Takebe**, *Cincinnati Children's Hospital Medical Center, USA/Tokyo Medical and Dental University and Yokohama City University, Japan*

[Fate Therapeutics](#) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

**16:30 EST Thought Leaders—Pivoting to the Future**

**Margaret A. Hamburg**, Co-Chair, WHO Expert Advisory Group On Developing Global Standards for Governance and Oversight of Human Genome Editing and Global Standards for Governance and Oversight of Human Genome Editing | Former FDA Commissioner

**Rajiv Kaul**, Sector Manager, Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund

**Andrew Plump**, President, Research & Development, Takeda Pharmaceutical Company Limited and Member of the Board of Directors

**Jim Tananbaum**, Founder and Chief Executive Officer of Foresite Capital

Interviewed by ISSCR Immediate Past President **Deepak Srivastava**, President, *Gladstone Institute/UCSF, USA*

**17:20 EST Concluding Remarks**

**Christine L. Mummery**, *ISSCR President / Leiden University Medical Center, Netherlands*

**Sponsored Industry Career Talks**

**Friday, 8 January**

**12:00-13:30 EST** ([view your time zone](#))

**12:00 EST Welcome**

**Keith Alm**, *ISSCR Chief Operating Officer, USA*

**Julia Tischler**, *ISSCR Membership Committee | École Polytechnique Fédérale de Lausanne, EPFL, Switzerland*

**12:05 EST [STEMCELL Technologies, Inc.](#)**

**Christine Genge**, *Manager, Recruitment*

**Nina Quiskamp**, *Scientist*

**12:26-12:31 EST Question and Answer** moderated by **Julia Tischler**, *ISSCR Membership Committee | École Polytechnique Fédérale de Lausanne, EPFL, Switzerland*

**12:35 EST [BlueRock Therapeutics](#)**

**Timsi Rao**, *Genome Sciences, Immunology*

**Stephany Sakharny**, *Senior Human Resources Manager*

**12:52-12:57 EST Question and Answer** moderated by **Julia Tischler**, *ISSCR Membership Committee | École Polytechnique Fédérale de Lausanne, EPFL, Switzerland*

**13:05 EST [ElevateBio](#)**

**Cherylene Plewa**, *Vice President, Cellular Engineering*

**Austin Thiel**, *Director Stem Cell Biology*

**13:18-13:23 EST Question and Answer** moderated by **Julia Tischler**, *ISSCR Membership Committee | École Polytechnique Fédérale de Lausanne, EPFL, Switzerland*

**13:30 EST Concluding Remarks**

**Keith Alm**, *ISSCR Chief Operating Officer, USA*

# ISSCR VISION2030 SPONSORS



**Gold Sponsor**



**Silver Sponsor**



**Silver Sponsor**



**Bronze Sponsor**



**Bronze Sponsor**



**Bronze Sponsor**



**Bronze Sponsor**